Licensing status

Publication and contact information



Adenosine A2A receptor (ADORA2A); ADORA2B; ecto-5ʹ-nucleotidase (NT5E; NT; CD73)

Mouse studies suggest inhibiting ADORA2A or ADORA2B could help prevent metastasis of CD73+ tumors. Expression of CD73 in tumor cells is known to enhance metastasis, but the downstream mechanisms underlying this effect were not known. In mouse models of breast cancer and melanoma, ectopic Cd73 expression promoted the conversion of AMP to adenosine and increased lung metastases compared with ectopic GFP expression. In a mouse model of Cd73+ metastatic melanoma, an ADORA2A or ADORA2B antagonist decreased lung metastases compared with no antagonists.
Researchers did not disclose next steps, which could include evaluating adenosine receptor antagonists in additional animal models of CD73+ tumors.
Kyowa Hakko Kirin Co. Ltd. markets Nouriast istradefylline, an ADORA2A antagonist, to treat Parkinson's disease (PD).
At least eight other companies have ADORA2A antagonists in Phase II testing or earlier to treat PD or other CNS disorders.

SciBX 6(36); doi:10.1038/scibx.2013.989
Published online Sept. 19, 2013

Patent and licensing status undisclosed

Beavis, P.A. et al. Proc. Natl. Acad. Sci. USA; published online Aug. 20, 2013;
Contact: Phillip K. Darcy, Peter MacCallum Cancer Centre, East Melbourne, Victoria Australia